The effect of probucol on atherosclerosis in streptozotocin-induced diabetic-hyperlipidemic APA hamsters in different stages of atherosclerosis

Experimental Animals

Volumn 51, Issue 5, 2002, Pages 457-464

  Horiuchi, Keiko ^a   Takatori, Atsushi ^a   Inenaga, Toshiaki ^a   Ohta, Etsuko ^a   Yamanouchi, Jun ^a   Kawamura, Seiji ^a   Ishii, Yoshiyuki ^a   Kyuwa, Shigeru ^a   Yoshikawa, Yasuhiro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

APA hamster; Diabetic atherosclerosis; Probucol

Indexed keywords

ANTIOXIDANT; CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LIPID PEROXIDE; PROBUCOL;

ANIMAL; AORTA; ARTERIOSCLEROSIS; ARTICLE; BLOOD; DISEASE MODEL; EXPERIMENTAL DIABETES MELLITUS; HAMSTER; HYPERLIPIDEMIA; MALE; PATHOLOGY;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ANTIOXIDANTS; AORTA; ARTERIOSCLEROSIS; CHOLESTEROL; CRICETINAE; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; HYPERLIPIDEMIAS; LIPID PEROXIDES; MALE; PROBUCOL;

ANIMALIA; CRICETINAE;

EID: 0041370247     PISSN: 13411357     EISSN: None     Source Type: Journal    
DOI: 10.1538/expanim.51.457     Document Type: Article

References (28)

1. Armstrong, D. and F. al-Awadi. 1991. Lipid peroxidation and retinopathy in streptozotocin-induced diabetes. Free. Radic. Biol. Med. 11: 433-436.
2. Bird, D.A., Tangirala, R.K., Fruebis, J., Steinberg, D., Witztum, J.L., and Palinski, W. 1998. Effect of probucol on LDL oxidation and atherosclerosis in LDL receptor-deficient mice. J. Lipid. Res. 39: 1079-1090.
3. El-Swefy, S., Schaefer, E.J., Seman, L.J., van Dongen, D., Sevanian, A., Smith, D.E., Ordovas, J.M., El-Sweidy, M., and Meydani, M. 2000. The effect of vitamin E, probucol, and lovastatin on oxidative status and aortic fatty lesions in hyperlipidemic-diabetic hamsters. Atherosclerosis 149: 277-286.
4. Grodos, D. and Tonglet, R. 1994. Scandinavian simvastatin study (4S). Lancet 344: 1768.
5. Han, J.S., Sugawara, Y., and Doi, K. 1992. Rapid induction of glomerular lipidosis in APA hamsters by streptozotocin. Int. J. Exp. Pathol. 73: 75-84.
6. Inazu, A., Koizumi, J., Kajinami, K., Kiyohar, T., Chichibu, K., and Mabuchi, H. 1999. Opposite effects on serum cholesteryl ester transfer protein levels between long-term treatments with pravastatin and probucol in patients with primary hypercholesterolemia and xanthoma. Atherosclerosis 145: 405-413.
7. Jain, S.K., McVie, R., Duett, J., and Herbst, J.J. 1989. Erythrocyte membrane lipid peroxidation and glycosylated hemoglobin in diabetes. Diabetes 38: 1539-1543.
8. Kesaniemi, Y.A. and Grundy, S.M. 1984. Influence of probucol on cholesterol and lipoprotein metabolism in man. J. Lipid. Res. 25: 780-790.
9. Kita, T., Ishii, K., Yokode, M., Kume, N., Nagano, Y., Arai, H., and Kawai, C. 1990. The role of oxidized low density lipoprotein in the pathogenesis of atherosclerosis. Eur. Heart. J. 11 Suppl E: 122-127.
10. Kita, T., Nagano, Y., Yokode, M., Ishii, K., Kume, N., Ooshima, A., Yoshida, H., and Kawai, C. 1987. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc. Natl. Acad. Sci. USA. 84: 5928-5931.
11. Maxwell, S.R., Thomason, H., Sandler, D., Leguen, C., Baxter, M.A., Thorpe, G.H., Jones, A.F., and Barnett, A.H. 1997. Antioxidant status in patients with uncomplicated insulin-dependent and non-insulin-dependent diabetes mellitus. Eur. J. Clin. Invest. 27: 484-490.
12. Nagano, Y., Nakamura, T., Matsuzawa, Y., Cho, M., Ueda, Y., and Kita, T. 1992. Probucol and atherosclerosis in the Watanabe heritable hyperlipidemic rabbit - long-term antiatherogenic effect and effects on established plaques. Atherosclerosis 92: 131-140.
13. O'Brien, K., Nagano, Y., Gown, A., Kita, T., and Chait, A. 1991. Probucol treatment affects the cellular composition but not anti- oxidized low density lipoprotein immunoreactivity of plaques from Watanabe heritable hyperlipidemic rabbits. Arterioscler. Thromb. 11: 751-759.
14. Parker, R.A., Sabrah, T., Cap, M., and Gill, B.T. 1995. Relation of vascular oxidative stress, alpha-tocopherol, and hypercholesterolemia to early atherosclerosis in hamsters. Arterioscler. Thromb. Vasc. Biol. 15: 349-358.
15. Regnstrom, J., Walldius, G., Hadell, K., Johansson, J., Holme, I., Olsson, A.G., and Nilsson, J. 1994. Influence of lipoprotein lipids, dietary fat and smoking on macrophage degradation of native and oxidized low density lipoprotein. Atherosclerosis 110: 13-23.
16. Sacks, F.M., Pfeffer, M.A., Moye, L.A., Rouleau, J.L., Rutherford, J.D., Cole, T.G., Brown, L., Warnica, J.W., Arnold, J.M., Wun, C.C., Davis, B.R., and Braunwald, E. 1996. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med. 335: 1001-1009.
17. Shepherd, J. 1995. The West of Scotland Coronary Prevention Study: a trial of cholesterol reduction in Scottish men. Am. J. Cardiol. 76: 113C-117C.
18. Sobala, G., Menzel, E.J., and Sinzinger, H. 2001. Calcium antagonists as inhibitors of in vitro low density lipoprotein oxidation and glycation. Biochem. Pharmacol. 61: 373-379.
19. Takatori, A., Nishida, E., Inenaga, T., Horiuchi, K., Kawamura, S., Itagaki, S., and Yoshikawa, Y. 2002. Functional and histochemical analysis on pancreatic islets of APA hamsters with SZ-induced hyperglycemia and hyperlipidemia. Exp. Anim. 51: 9-17.
20. Takemura, T., Sakai, M., Matsuda, H., Matsumura, T., Biwa, T., Anami, Y., Nishikawa, T., Sasahara, T., and Shichiri, M. 2000. Effects of probucol on cholesterol metabolism in mouse peritoneal macrophages: inhibition of HDL-mediated cholesterol efflux. Atherosclerosis 152: 347-357.
21. Tilly-Kiesi, M., Syvanne, M., Kuusi, T., Lahdenpera, S., and Taskinen, M.R. 1992. Abnormalities of low density lipoproteins in normolipidemic type II diabetic and nondiabetic patients with coronary artery disease. J. Lipid. Res. 33: 333-342.
22. Uchida, N., Shuto, Y., and Oikawa, S. 2001. [Diabetes mellitus and hyperlipidemia]. Nippon Rinsho. 59 Suppl 3: 733-737.
23. Walldius, G., Erikson, U., Olsson, A.G., Bergstrand, L., Hadell, K., Johansson, J., Kaijser, L., Lassvik, C., Molgaard, J., Nilsson, S., Schafer-Elinder, L., Stenport, G., and Holme, I. 1994. The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). Am. J. Cardiol. 74: 875-883.
24. Weingand, K.W. and Daggy, B.P. 1990. Quantification of high-density-lipoprotein cholesterol in plasma from hamsters by differential precipitation. Clin. Chem. 36: 575.
25. Wilson, T.A., Meservey, C.M., and Nicolosi, R.J. 1998. Soy lecithin reduces plasma lipoprotein cholesterol and early atherogenesis in hypercholesterolemic monkeys and hamsters: beyond linoleate. Atherosclerosis 140: 147-153.
26. Yamamoto, A., Matsuzawa, Y., Yokoyama, S., Funahashi, T., Yamamura, T., and Kishino, B. 1986. Effects of probucol on xanthomata regression in familial hypercholesterolemia. Am. J. Cardiol. 57: 29H-35H.
27. Yamanouchi, J., Nishida, E., Itagaki, S., Kawamura, S., Doi, K., and Yoshikawa, Y. 2000. Aortic atheromatous lesions developed in APA hamsters with streptozotocin induced diabetes: a new animal model for diabetic atherosclerosis. 1. Histopathological studies. Exp. Anim. 49: 259-266.
28. Yoshikawa, T., Shimano, H., Chen, Z., Ishibashi, S., and Yamada, N. 2001. Effects of Probucol on Atherosclerosis of apoE-Deficient or LDL Receptor-Deficient Mice. Horm. Metab. Res. 33: 472-479.